Intelligent Medicine Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It intends to identify business opportunities in the field of life science. The company was incorporated in 2021 and is based in Bethesda, Maryland.
IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
Fastest customizable press release news feed in the world
Intelligent Medicine Acquisition Corp. (NASDAQ:IQMD) (the "Company"), a blank-check company formed for the purpose of acquiring or merging with one or more businesses, today announced that because the Company does not believe it will be able to consummate an initial business combination within the time period required by its Amended and Restated Certificate of Incorporation (the "Charter"), the Company intends to dissolve and liquidate in accordance with the provisions of the Charter, and will redeem all of the outstanding shares of Class A common stock that were included in the units issued in its initial public offering (the "Public Shares"), at a per-share redemption price of approximate
Intelligent Medicine Acquisition Corp. (NASDAQ:IQMD) (the "Company") announced today that it has postponed the Company's Special Meeting of Stockholders to be held on February 3, 2023, at 9:30 a.m. Eastern Time until February 8, 2023, at 9:30 a.m. Eastern Time. The postponed Special Meeting will be completely virtual, and stockholders will be able to attend the special meeting online, vote and submit questions by visiting https://www.cstproxy.com/iqmdspac/2023. There will be no change in the record date as a result of this postponement or the date by which stockholders must have elected to redeem their public shares, and proxies tendered prior to the postponed date will not need to be voted
Kroll, the leading provider of data, technology and insights related to risk, governance and growth, announced today Patience Marime-Ball will be a Senior Advisor to Kroll's Environmental, Social and Governance (ESG) Advisory Services Committee. Kroll provides an extensive range of advisory support and technology solutions to address growing ESG challenges, create sustainable value and growth, and effectively manage risk. Marime-Ball will play a critical role advising Kroll and its clients on how to drive meaningful changes that will help benefit people and the planet. "We're excited to welcome Patience as a new Senior Advisor to Kroll on ESG," said Jake Silverman, Chief Executive Officer
15-12G - Intelligent Medicine Acquisition Corp. (0001850051) (Filer)
25-NSE - Intelligent Medicine Acquisition Corp. (0001850051) (Subject)
8-K - Intelligent Medicine Acquisition Corp. (0001850051) (Filer)
10-K - Intelligent Medicine Acquisition Corp. (0001850051) (Filer)
8-K - Intelligent Medicine Acquisition Corp. (0001850051) (Filer)
8-K - Intelligent Medicine Acquisition Corp. (0001850051) (Filer)
NT 10-K - Intelligent Medicine Acquisition Corp. (0001850051) (Filer)
8-K - Intelligent Medicine Acquisition Corp. (0001850051) (Filer)
DEFA14A - Intelligent Medicine Acquisition Corp. (0001850051) (Filer)
8-K - Intelligent Medicine Acquisition Corp. (0001850051) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - Intelligent Medicine Acquisition Corp. (0001850051) (Issuer)
4 - Intelligent Medicine Acquisition Corp. (0001850051) (Issuer)
4 - Intelligent Medicine Acquisition Corp. (0001850051) (Issuer)
3/A - Intelligent Medicine Acquisition Corp. (0001850051) (Issuer)
3 - Intelligent Medicine Acquisition Corp. (0001850051) (Issuer)
Live Leadership Updates
Kroll, the leading provider of data, technology and insights related to risk, governance and growth, announced today Patience Marime-Ball will be a Senior Advisor to Kroll's Environmental, Social and Governance (ESG) Advisory Services Committee. Kroll provides an extensive range of advisory support and technology solutions to address growing ESG challenges, create sustainable value and growth, and effectively manage risk. Marime-Ball will play a critical role advising Kroll and its clients on how to drive meaningful changes that will help benefit people and the planet. "We're excited to welcome Patience as a new Senior Advisor to Kroll on ESG," said Jake Silverman, Chief Executive Officer
This live feed shows all institutional transactions in real time.
SC 13G - Intelligent Medicine Acquisition Corp. (0001850051) (Subject)
SC 13G/A - Intelligent Medicine Acquisition Corp. (0001850051) (Subject)
SC 13D - Intelligent Medicine Acquisition Corp. (0001850051) (Subject)
SC 13G/A - Intelligent Medicine Acquisition Corp. (0001850051) (Subject)
SC 13G/A - Intelligent Medicine Acquisition Corp. (0001850051) (Subject)
SC 13G/A - Intelligent Medicine Acquisition Corp. (0001850051) (Subject)
SC 13G - Intelligent Medicine Acquisition Corp. (0001850051) (Subject)
SC 13G - Intelligent Medicine Acquisition Corp. (0001850051) (Subject)
SC 13G/A - Intelligent Medicine Acquisition Corp. (0001850051) (Subject)